An epithelial-to-mesenchymal transition induced extracellular vesicle prognostic signature in non-small cell lung cancer
Richard J. Lobb, Kekoolani S. Visan, Li‐Ying Wu, Emma L. Norris, Marcus L. Hastie, Sarah Everitt, Ian A. Yang, Rayleen Bowman, Shankar Siva, Jill E. Larsen, Jeffrey J. Gorman, Michael MacManus, Antoine Leimgruber, Kwun M. Fong, Andreas Möller
Abstract
. Non-small cell lung cancer (NSCLC) patients have a very poor overall five-year survival rate of only 10-20%. Currently, TNM staging is the gold standard for predicting overall survival and selecting optimal initial treatment options for NSCLC patients, including those with curable stages of disease. However, many patients with locoregionally-confined NSCLC relapse and die despite curative-intent interventions, indicating a need for intensified, individualised therapies. Epithelial-to-mesenchymal transition (EMT), the phenotypic depolarisation of epithelial cells to elongated, mesenchymal cells, is associated with metastatic and treatment-refractive cancer. We demonstrate here that EMT-induced protein changes in small extracellular vesicles are detectable in NSCLC patients and have prognostic significance. Overall, this work describes a novel prognostic biomarker signature that identifies potentially-curable NSCLC patients at risk of developing metastatic NSCLC, thereby enabling implementation of personalised treatment decisions.